Day: April 10, 2025

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to follow Company to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-person and virtual R&D Day on Tuesday, April 15ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has completed enrollment in both Phase 3 DIAMOND-1...

Eviden will bring together a unique comprehensive set of AI capabilities – supercomputing power for AI, software layer and AI use-cases development Paris, France – April 10, 2025 – Eviden, the Atos Group business leading in digital, cloud, big data and security today announces the signature of a 50-million-euro contract with the Serbia’s Office for IT and eGovernment. Together, Eviden and the Serbian administration will deploy a National AI Factory – composed of an AI Center of Excellence and a leading AI-dedicated supercomputing platform – aiming to accelerate Serbia’s AI capabilities and foster innovation across key sectors while reinforcing its technological autonomy using European technologies. More than just a simple infrastructure, an AI Factory is an extensive and complete set of shared AI-dedicated assets – talents, expertise,...

Press release no. 1-2025Copenhagen, April 10, 2025 Konsolidator enters partnership with Exsitec to accelerate growth in the Nordics Today, Konsolidator enters a new strategic partnership with Exsitec AB, one of the most prominent players in the Nordic region, to implement and manage business-supporting IT systems. The partnership allows Konsolidator to be fully partner-driven in Sweden and Norway, thereby significantly advancing the company’s 2025–2027 strategy, Resilient Growth, which prioritizes scaling growth through strategic partnerships. Exsitec, a long-standing customer of Konsolidator, brings in-depth product knowledge and integration experience. Furthermore, with shared customers and strong expertise in finance IT, Exsitec is an ideal partner for making Konsolidator available to more companies in the Nordics, especially in the...

PR No: C3330C STMicroelectronics details company-wide program to reshape manufacturing footprint and resize global cost baseIncreasing efficiency, automation, and AI will strengthen ST’s key technology R&D, design and high-volume assets for advanced manufacturing in Europe.Planned investments over FY2025, 2026 and 2027 to focus on advanced manufacturing infrastructure in 300mm silicon, 200mm silicon carbide, and technology R&D, for the benefit of customers globally.Company-wide program, including both the previously disclosed resizing of cost base and the reshaping of manufacturing footprint, expected to see up to 2,800 people leaving the company globally on a voluntary basis over 3 years, on top of normal attrition.Confirmation of annual cost savings target in the high triple-digit million-dollar range exiting 2027.Geneva,...

Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion’s research and development strategy. Discussions will highlight Esperion’s advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indication and...

Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE NEWSWIRE) — Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, today announced the expansion of its Chief Strategy Office (CSO) with the addition of Christopher Hall and Kathya Capote Peimbert. Their extensive experience in e-invoicing, global tax compliance and ERP integration further reinforces Vertex’s continued commitment to innovation and excellence, helping businesses navigate an increasingly complex regulatory landscape. Hall and Peimbert join a distinguished group of tax leaders across the CSO and Chief Tax Office who have played a pivotal role in shaping Vertex’s tax technology...

S.S. Juve Stabia’s upcoming Serie B fixture against Cremonese will be broadcast in English live and free in the United States, Canada and United Kingdom via Destination CalcioS.S. Juve Stabia’s upcoming Serie B fixture against Cremonese will be broadcast in English live and free in the United States, Canada and United Kingdom via Destination CalcioS.S. Juve Stabia’s upcoming Serie B fixture against Cremonese will be broadcast in English live and free in the United States, Canada and United Kingdom via Destination Calcio Dublin, Ireland and Milan, Italy, April 10, 2025 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera Holdings” or the “Company”) (Nasdaq: BREA), an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s football clubs through a multi-club ownership (“MCO”)...

Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of the previously disclosed blinded safety and pharmacokinetic (PK) data from the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). These data will be featured in an ePoster Flash Session oral presentation...